Explain this page
Arphra AIPlain-English read on Edwards Lifesciences Corporation’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.95% | +2.25% | +4.98% | +1.12% | +4.07% | +3.41% | +12.88% | +3.30% | -5.59% | +159.04% | +6311.64% |
Aftermarket
LiveLast trade
$88.00
191 sh
Bid
$87.60
2 sh
Ask
$89.00
600 sh
Spread
$1.400
Sector & industry today
LiveSectors
- Technology+3.30%
- Basic Materials+0.98%
- Energy+0.83%
- Consumer Cyclical+0.49%
- Industrials+0.25%
- Communication Services+0.13%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.84%
- Utilities-1.15%
- Real Estate-1.32%
Top industries (issuer's industry highlighted)
- Medical - Devices-0.34%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Consulting Services+5.28%
- Coal+5.20%
- Manufacturing - Metal Fabrication+4.24%
- Staffing & Employment Services+4.08%
- Gambling, Resorts & Casinos+3.71%
- Broadcasting+3.70%
- Integrated Freight & Logistics+3.68%
- REIT - Healthcare Facilities-3.49%
- Software - Application+3.44%
Fair value
Football field →Weighted blend
$70.64
-19.87% vs spot
Recommendation
Underweight
15 of 16 methods
Method spread
3bull11bear
±5% threshold
Analyst PT consensus: $96.53 (+9.49%)
Total assets
$13.7B
Total debt
$705.4M
Cash & equiv
$2.94B
Operating CF
$1.6B
Free cash flow
$1.34B
Buybacks
-$893.4M
Analyst view
DB · price_targets + analyst_gradesConsensus target
$96.53
+9.49% upside
Low
$85.00
Median
$95.00
High
$110.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Edwards Lifesciences Corporation (EW) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- Edwards Lifesciences Announces Appointment of CFObusinesswire.com·May 04, 2026
- Edwards Lifesciences Announces Appointment of CFObusinesswire.com·May 04, 2026
- Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissuebusinesswire.com·May 02, 2026
- Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences' Resilia Tissuebusinesswire.com·May 02, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $1.65B | $380.7M | $0.66 |
| Q4 Dec 2025 | $1.57B | $91.2M | $0.16 |
| Q3 Sep 2025 | $1.55B | $291.1M | $0.50 |
| Q2 Jun 2025 | $1.53B | $329.8M | $0.56 |
| Q1 Mar 2025 | $1.41B | $358M | $0.61 |
| Q4 Dec 2024 | $1.39B | $385.6M | $0.65 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Markowitz Wayne officer: CVP, JAPAC | Sell | 593 | $47.28K | May 11, 2026 |
Lippis Daniel J. officer: CVP, TAVR | Sell | 1,019 | $85.58K | May 04, 2026 |
Lippis Daniel J. officer: CVP, TAVR | Sell | 19 | $1.6K | May 01, 2026 |
Lippis Daniel J. officer: CVP, TAVR | Sell | 1,000 | $82.99K | May 01, 2026 |
Ullem Scott B. officer: CVP, Chief Financial Officer | Sell | 4,676 | $376.4K | Apr 09, 2026 |
Ullem Scott B. officer: CVP, Chief Financial Officer | Sell | 8,324 | $664.14K | Apr 09, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $6.07B | $1.64B | $1.07B | $1.83 | +17.69% |
| FY 2024 | $5.44B | $1.38B | $4.17B | $6.97 | +76.75% |
| FY 2023 | $5.01B | $1.43B | $1.4B | $2.30 | +27.99% |
| FY 2022 | $5.38B | $1.7B | $1.52B | $2.44 | +28.28% |
| FY 2021 | $5.23B | $1.61B | $1.5B | $2.38 | +28.73% |